Riverview Trust Company’s Jazz Pharmaceuticals JAZZ Stock Holding History

Riverview Trust Company’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6	Closed	-$739	–	723
2024 Q4	$739	Hold	6	–	–	﹤0.01%	695
2024 Q3	$668	Buy	+6	New	+$657	﹤0.01%	730
2023 Q4	–	Sell	-112	Closed	-$14.5K	–	365
2023 Q3	$14.5K	Hold	112	–	–	0.01%	560
2023 Q2	$13.9K	Hold	112	–	–	0.01%	584
2023 Q1	$16.4K	Hold	112	–	–	0.02%	426
2022 Q4	$18K	Hold	112	–	–	0.02%	356
2022 Q3	$15K	Hold	112	–	–	0.01%	431
2022 Q2	$17K	Hold	112	–	–	0.01%	438
2022 Q1	$17K	Buy	+112	New	+$16.3K	0.01%	560
2019 Q4	–	Sell	-1,589	Closed	-$204K	–	275
2019 Q3	$204K	Hold	1,589	–	–	0.14%	104
2019 Q2	$227K	Hold	1,589	–	–	0.16%	100
2019 Q1	$227K	Hold	1,589	–	–	0.17%	99
2018 Q4	$197K	Buy	+1,589	New	+$236K	0.15%	96

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Riverview Trust Company's JAZZ Position: Q1 2025 in Review

Riverview Trust Company sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2025, closing a stake of 6 shares — an estimated $739 sold.

Riverview Trust Company first reported a position in JAZZ in Q4 2018 and held it in 13 quarters. The position peaked at $227K in Q2 2019. 550 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

Riverview Trust Company reported no remaining Jazz Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Riverview Trust Company sold 6 Jazz Pharmaceuticals shares in Q1 2025, an estimated $739.
Riverview Trust Company first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 13 quarters.
Riverview Trust Company's Jazz Pharmaceuticals position peaked at $227K in Q2 2019.
550 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Riverview Trust Company's 13F filing for Q1 2025, filed 11 Apr 2025.